Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells
Abstract
:1. Introduction
2. Results
2.1. 13C-Glucose Tracing in Proneural and Mesenchymal BTICs
2.2. Extracellular Amino Acid Concentrations
2.3. mRNA Microarrays of Metabolic Hallmarks from Proneural and Mesenchymal BTICs
2.4. Effects of Metformin on Apoptosis and Autophagy of BTICs
2.5. Metformin Treatment in Mice
3. Discussion
4. Materials and Methods
4.1. Cell Based Methods
4.1.1. Tumor Specimens and Enrichment of BTICs
4.1.2. Treatment of BTICs with Metformin
4.1.3. Annexin-V/7-AAD FACS Analysis
4.1.4. LC-3 I/II Staining
4.2. Protein-Based Methods
Western Blot
4.3. mRNA-Based Methods
Microarray Analysis, Clustering, and Gene Set Enrichment Analysis
4.4. Metabolic Methods
4.4.1. Determination of Extracellular Metabolite Concentrations
4.4.2. 13C-Glucose Isotope Tracing
4.5. Orthotopic BTIC Mouse Model
4.5.1. Preparation and Conduct of Mouse Model
4.5.2. H&E Staining and Immunofluorescence Staining for MCT4, GFAP and SOX-2
4.6. Statistics
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Verdugo, E.; Puerto, I.; Medina, M.A. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun. 2022, 42, 1083–1111. [Google Scholar] [CrossRef] [PubMed]
- Stupp, R.; Hegi, M.E.; Gorlia, T.; Erridge, S.C.; Perry, J.; Hong, Y.K.; Aldape, K.D.; Lhermitte, B.; Pietsch, T.; Grujicic, D.; et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated mgmt promoter (centric eortc 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 1100–1108. [Google Scholar] [CrossRef] [PubMed]
- Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [Google Scholar] [CrossRef]
- Stupp, R.; Taillibert, S.; Kanner, A.; Read, W.; Steinberg, D.; Lhermitte, B.; Toms, S.; Idbaih, A.; Ahluwalia, M.S.; Fink, K.; et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 2017, 318, 2306–2316. [Google Scholar] [CrossRef]
- Lathia, J.D.; Mack, S.C.; Mulkearns-Hubert, E.E.; Valentim, C.L.; Rich, J.N. Cancer stem cells in glioblastoma. Genes Dev. 2015, 29, 1203–1217. [Google Scholar] [CrossRef] [PubMed]
- Mao, P.; Joshi, K.; Li, J.; Kim, S.H.; Li, P.; Santana-Santos, L.; Luthra, S.; Chandran, U.R.; Benos, P.V.; Smith, L.; et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1a3. Proc. Natl. Acad. Sci. USA 2013, 110, 8644–8649. [Google Scholar] [CrossRef]
- Seliger, C.; Meyer, A.-L.; Leidgens, V.; Rauer, L.; Moeckel, S.; Jachnik, B.; Proske, J.; Dettmer, K.; Rothhammer-Hampl, T.; Kaulen, L.D.; et al. Metabolic heterogeneity of brain tumor cells of proneural and mesenchymal origin. Int. J. Mol. Sci. 2022, 23, 11629. [Google Scholar] [CrossRef]
- Caniglia, J.L.; Jalasutram, A.; Asuthkar, S.; Sahagun, J.; Park, S.; Ravindra, A.; Tsung, A.J.; Guda, M.R.; Velpula, K.K. Beyond glucose: Alternative sources of energy in glioblastoma. Theranostics 2021, 11, 2048–2057. [Google Scholar] [CrossRef]
- Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in pdgfra, idh1, egfr, and nf1. Cancer Cell 2010, 17, 98–110. [Google Scholar] [CrossRef]
- Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.; Colman, H.; Soroceanu, L.; et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157–173. [Google Scholar] [CrossRef] [Green Version]
- Nakano, I. Therapeutic potential of targeting glucose metabolism in glioma stem cells. Expert Opin. Ther. Targets 2014, 18, 1233–1236. [Google Scholar] [CrossRef]
- Ohno, M.; Kitanaka, C.; Miyakita, Y.; Tanaka, S.; Sonoda, Y.; Mishima, K.; Ishikawa, E.; Takahashi, M.; Yanagisawa, S.; Ohashi, K.; et al. Metformin with temozolomide for newly diagnosed glioblastoma: Results of phase i study and a brief review of relevant studies. Cancers 2022, 14, 4222. [Google Scholar] [CrossRef]
- Sesen, J.; Dahan, P.; Scotland, S.J.; Saland, E.; Dang, V.T.; Lemarie, A.; Tyler, B.M.; Brem, H.; Toulas, C.; Cohen-Jonathan Moyal, E.; et al. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS ONE 2015, 10, e0123721. [Google Scholar] [CrossRef]
- Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348 Pt 3, 607–614. [Google Scholar] [CrossRef] [PubMed]
- Oizel, K.; Yang, C.; Renoult, O.; Gautier, F.; Do, Q.N.; Joalland, N.; Gao, X.; Ko, B.; Vallette, F.; Ge, W.P.; et al. Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model. Cancer Metab. 2020, 8, 9. [Google Scholar] [CrossRef]
- Moeckel, S.; Meyer, K.; Leukel, P.; Heudorfer, F.; Seliger, C.; Stangl, C.; Bogdahn, U.; Proescholdt, M.; Brawanski, A.; Vollmann-Zwerenz, A.; et al. Response-predictive gene expression profiling of glioma progenitor cells in vitro. PLoS ONE 2014, 9, e108632. [Google Scholar] [CrossRef] [PubMed]
- Liu, R.; Zeng, L.W.; Gong, R.; Yuan, F.; Shu, H.B.; Li, S. Mtorc1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis. Nat. Commun. 2021, 12, 4227. [Google Scholar] [CrossRef] [PubMed]
- Duan, J.J.; Cai, J.; Guo, Y.F.; Bian, X.W.; Yu, S.C. Aldh1a3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 2016, 139, 965–975. [Google Scholar] [CrossRef]
- Mecca, C.; Giambanco, I.; Donato, R.; Arcuri, C. Targeting mtor in glioblastoma: Rationale and preclinical/clinical evidence. Dis. Markers 2018, 2018, 9230479. [Google Scholar] [CrossRef] [PubMed]
- Seliger, C.; Meyer, A.L.; Renner, K.; Leidgens, V.; Moeckel, S.; Jachnik, B.; Dettmer, K.; Tischler, U.; Gerthofer, V.; Rauer, L.; et al. Metformin inhibits proliferation and migration of glioblastoma cells independently of tgf-beta2. Cell Cycle 2016, 15, 1755–1766. [Google Scholar] [CrossRef] [Green Version]
- Kim, Y.C.; Guan, K.L. Mtor: A pharmacologic target for autophagy regulation. J. Clin. Investig. 2015, 125, 25–32. [Google Scholar] [CrossRef] [PubMed]
- Tanida, I.; Ueno, T.; Kominami, E. Lc3 and autophagy. Methods Mol. Biol. 2008, 445, 77–88. [Google Scholar]
- Harhaji-Trajkovic, L.; Vilimanovich, U.; Kravic-Stevovic, T.; Bumbasirevic, V.; Trajkovic, V. Ampk-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J. Cell Mol. Med. 2009, 13, 3644–3654. [Google Scholar] [CrossRef]
- Isakovic, A.; Harhaji, L.; Stevanovic, D.; Markovic, Z.; Sumarac-Dumanovic, M.; Starcevic, V.; Micic, D.; Trajkovic, V. Dual antiglioma action of metformin: Cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol. Life Sci. 2007, 64, 1290–1302. [Google Scholar] [CrossRef] [PubMed]
- De Santis, M.C.; Porporato, P.E.; Martini, M.; Morandi, A. Signaling pathways regulating redox balance in cancer metabolism. Front. Oncol. 2018, 8, 126. [Google Scholar] [CrossRef]
- Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.; Clish, C.B.; Mootha, V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336, 1040–1044. [Google Scholar] [CrossRef]
- Li, G.; Li, Y.; Liu, X.; Wang, Z.; Zhang, C.; Wu, F.; Jiang, H.; Zhang, W.; Bao, Z.; Wang, Y.; et al. Aldh1a3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. Cell Death Dis. 2018, 9, 1190. [Google Scholar] [CrossRef]
- Sullivan, K.E.; Rojas, K.; Cerione, R.A.; Nakano, I.; Wilson, K.F. The stem cell/cancer stem cell marker aldh1a3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells. Oncotarget 2017, 8, 22325–22343. [Google Scholar] [CrossRef] [PubMed]
- Pyaskovskaya, O.N.; Kolesnik, D.L.; Fedorchuk, A.G.; Gorbik, G.V.; Solyanik, G.I. Cytotoxic activity of metformin in vitro does not correlate with its antitumor action in vivo. Exp. Oncol. 2017, 39, 264–268. [Google Scholar] [CrossRef]
- Flavahan, W.A.; Wu, Q.; Hitomi, M.; Rahim, N.; Kim, Y.; Sloan, A.E.; Weil, R.J.; Nakano, I.; Sarkaria, J.N.; Stringer, B.W.; et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 2013, 16, 1373–1382. [Google Scholar] [CrossRef]
- Koppula, P.; Zhang, Y.; Shi, J.; Li, W.; Gan, B. The glutamate/cystine antiporter slc7a11/xct enhances cancer cell dependency on glucose by exporting glutamate. J. Biol. Chem. 2017, 292, 14240–14249. [Google Scholar] [CrossRef] [Green Version]
- Bhutia, Y.D.; Babu, E.; Ramachandran, S.; Ganapathy, V. Amino acid transporters in cancer and their relevance to “glutamine addiction”: Novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015, 75, 1782–1788. [Google Scholar] [CrossRef]
- Eagle, H. Nutrition needs of mammalian cells in tissue culture. Science 1955, 122, 501–514. [Google Scholar] [CrossRef] [PubMed]
- Annibali, D.; Whitfield, J.R.; Favuzzi, E.; Jauset, T.; Serrano, E.; Cuartas, I.; Redondo-Campos, S.; Folch, G.; Gonzalez-Junca, A.; Sodir, N.M.; et al. Myc inhibition is effective against glioma and reveals a role for myc in proficient mitosis. Nat. Commun. 2014, 5, 4632. [Google Scholar] [CrossRef]
- Cluntun, A.A.; Lukey, M.J.; Cerione, R.A.; Locasale, J.W. Glutamine metabolism in cancer: Understanding the heterogeneity. Trends Cancer 2017, 3, 169–180. [Google Scholar] [CrossRef] [PubMed]
- Moreira Franco, Y.E.; Alves, M.J.; Uno, M.; Moretti, I.F.; Trombetta-Lima, M.; de Siqueira Santos, S.; Dos Santos, A.F.; Arini, G.S.; Baptista, M.S.; Lerario, A.M.; et al. Glutaminolysis dynamics during astrocytoma progression correlates with tumor aggressiveness. Cancer Metab. 2021, 9, 18. [Google Scholar] [CrossRef] [PubMed]
- Gerthofer, V.; Kreutz, M.; Renner, K.; Jachnik, B.; Dettmer, K.; Oefner, P.; Riemenschneider, M.J.; Proescholdt, M.; Vollmann-Zwerenz, A.; Hau, P.; et al. Combined modulation of tumor metabolism by metformin and diclofenac in glioma. Int. J. Mol. Sci. 2018, 19, 2586. [Google Scholar] [CrossRef]
- Leidgens, V.; Proske, J.; Rauer, L.; Moeckel, S.; Renner, K.; Bogdahn, U.; Riemenschneider, M.J.; Proescholdt, M.; Vollmann-Zwerenz, A.; Hau, P.; et al. Stattic and metformin inhibit brain tumor initiating cells by reducing stat3-phosphorylation. Oncotarget 2017, 8, 8250–8263. [Google Scholar] [CrossRef]
- Sato, A.; Sunayama, J.; Okada, M.; Watanabe, E.; Seino, S.; Shibuya, K.; Suzuki, K.; Narita, Y.; Shibui, S.; Kayama, T.; et al. Glioma-initiating cell elimination by metformin activation of foxo3 via ampk. Stem Cells Transl. Med. 2012, 1, 811–824. [Google Scholar] [CrossRef] [PubMed]
- Wurth, R.; Pattarozzi, A.; Gatti, M.; Bajetto, A.; Corsaro, A.; Parodi, A.; Sirito, R.; Massollo, M.; Marini, C.; Zona, G.; et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of akt. Cell Cycle 2013, 12, 145–156. [Google Scholar] [CrossRef]
- Birsoy, K.; Possemato, R.; Lorbeer, F.K.; Bayraktar, E.C.; Thiru, P.; Yucel, B.; Wang, T.; Chen, W.W.; Clish, C.B.; Sabatini, D.M. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014, 508, 108–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Labuzek, K.; Suchy, D.; Gabryel, B.; Bielecka, A.; Liber, S.; Okopien, B. Quantification of metformin by the hplc method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol. Rep. 2010, 62, 956–965. [Google Scholar] [CrossRef]
- Jung, C.H.; Ro, S.H.; Cao, J.; Otto, N.M.; Kim, D.H. Mtor regulation of autophagy. FEBS Lett. 2010, 584, 1287–1295. [Google Scholar] [CrossRef] [PubMed]
- Chavez-Dominguez, R.; Perez-Medina, M.; Lopez-Gonzalez, J.S.; Galicia-Velasco, M.; Aguilar-Cazares, D. The double-edge sword of autophagy in cancer: From tumor suppression to pro-tumor activity. Front. Oncol. 2020, 10, 578418. [Google Scholar] [CrossRef]
- Shen, J.Z.; Wu, G.; Guo, S. Amino acids in autophagy: Regulation and function. Adv. Exp. Med. Biol. 2021, 1332, 51–66. [Google Scholar]
- Zeng, J.D.; Wu, W.K.K.; Wang, H.Y.; Li, X.X. Serine and one-carbon metabolism, a bridge that links mtor signaling and DNA methylation in cancer. Pharmacol. Res. 2019, 149, 104352. [Google Scholar] [CrossRef]
- Eisenberg-Lerner, A.; Kimchi, A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis 2009, 14, 376–391. [Google Scholar] [CrossRef] [PubMed]
- Memmott, R.M.; Mercado, J.R.; Maier, C.R.; Kawabata, S.; Fox, S.D.; Dennis, P.A. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev. Res. 2010, 3, 1066–1076. [Google Scholar] [CrossRef]
- Lee, J.E.; Lim, J.H.; Hong, Y.K.; Yang, S.H. High-dose metformin plus temozolomide shows increased anti-tumor effects in glioblastoma in vitro and in vivo compared with monotherapy. Cancer Res. Treat. 2018, 50, 1331–1342. [Google Scholar] [CrossRef]
- Yang, S.H.; Li, S.; Lu, G.; Xue, H.; Kim, D.H.; Zhu, J.J.; Liu, Y. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Oncotarget 2016, 7, 78787–78803. [Google Scholar] [CrossRef]
- Wang, Y.; Meng, Y.; Zhang, S.; Wu, H.; Yang, D.; Nie, C.; Hu, Q. Phenformin and metformin inhibit growth and migration of ln229 glioma cells in vitro and in vivo. OncoTargets Ther. 2018, 11, 6039–6048. [Google Scholar] [CrossRef] [PubMed]
- Pereira, F.V.; Melo, A.C.L.; Low, J.S.; de Castro, I.A.; Braga, T.T.; Almeida, D.C.; Batista de Lima, A.G.U.; Hiyane, M.I.; Correa-Costa, M.; Andrade-Oliveira, V.; et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget 2018, 9, 25808–25825. [Google Scholar] [CrossRef] [Green Version]
- Smith, S.J.; Rowlinson, J.; Estevez-Cebrero, M.; Onion, D.; Ritchie, A.; Clarke, P.; Wood, K.; Diksin, M.; Lourdusamy, A.; Grundy, R.G.; et al. Metabolism-based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential. Neurooncol. Adv. 2020, 2, vdaa087. [Google Scholar] [CrossRef]
- Telford, W.G.; Komoriya, A.; Packard, B.Z. Multiparametric analysis of apoptosis by flow and image cytometry. Methods Mol. Biol. 2004, 263, 141–160. [Google Scholar]
- Li, X.; Zhang, Y.; Wang, J.; Li, Y.; Wang, Y.; Shi, F.; Hong, L.; Li, L.; Diao, H. Zvad alleviates experimental autoimmune hepatitis in mice by increasing the sensitivity of macrophage to tnfr1-dependent necroptosis. J. Autoimmun. 2022, 133, 102904. [Google Scholar] [CrossRef] [PubMed]
- Smyth, G.K.; Michaud, J.; Scott, H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005, 21, 2067–2075. [Google Scholar] [CrossRef] [PubMed]
- Singer, K.; Dettmer, K.; Unger, P.; Schonhammer, G.; Renner, K.; Peter, K.; Siska, P.J.; Berneburg, M.; Herr, W.; Oefner, P.J.; et al. Topical diclofenac reprograms metabolism and immune cell infiltration in actinic keratosis. Front. Oncol. 2019, 9, 605. [Google Scholar] [CrossRef]
- Heinrich, P.; Kohler, C.; Ellmann, L.; Kuerner, P.; Spang, R.; Oefner, P.J.; Dettmer, K. Correcting for natural isotope abundance and tracer impurity in ms-, ms/ms- and high-resolution-multiple-tracer-data from stable isotope labeling experiments with isocorrector. Sci. Rep. 2018, 8, 17910. [Google Scholar] [CrossRef] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Seliger, C.; Rauer, L.; Wüster, A.-L.; Moeckel, S.; Leidgens, V.; Jachnik, B.; Ammer, L.-M.; Heckscher, S.; Dettmer, K.; Riemenschneider, M.J.; et al. Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells. Int. J. Mol. Sci. 2023, 24, 3199. https://doi.org/10.3390/ijms24043199
Seliger C, Rauer L, Wüster A-L, Moeckel S, Leidgens V, Jachnik B, Ammer L-M, Heckscher S, Dettmer K, Riemenschneider MJ, et al. Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells. International Journal of Molecular Sciences. 2023; 24(4):3199. https://doi.org/10.3390/ijms24043199
Chicago/Turabian StyleSeliger, Corinna, Lisa Rauer, Anne-Louise Wüster, Sylvia Moeckel, Verena Leidgens, Birgit Jachnik, Laura-Marie Ammer, Simon Heckscher, Katja Dettmer, Markus J. Riemenschneider, and et al. 2023. "Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells" International Journal of Molecular Sciences 24, no. 4: 3199. https://doi.org/10.3390/ijms24043199